Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
Bristol Myers' (BMY) Lung Cancer Drug NDA Gets Priority Review
01:16pm, Wednesday, 31'st May 2023
Bristol Myers' (BMY) NDA for repotrectinib for treating patients with NSCLC receives Priority Review from the FDA.
Is Bristol Myers Squibb a Top Dividend Stock?
11:15am, Wednesday, 31'st May 2023
Bristol Myers Squibb is a company in transition. The uncertainty created by its upcoming leadership change and ongoing portfolio churn has kept investors at bay this year.
Bloomsbury Publishing reports record results as consumers turn to books
03:22am, Wednesday, 31'st May 2023
Bloomsbury Publishing said it delivered “record results” and forecasts revenues and profits to grow in the current financial year. Sales were up 15% to £264.1mln in the year to 28 February 2023,
B&M and Bloomsbury full-year results on Wednesday
11:01am, Tuesday, 30'th May 2023
On Wednesday, the focus will turn to budget retailer, B&M European Value Retail SA (LSE:BME), and all eyes will be on current trading and outlook, according to Barclays. Analysts expect underlying ea
High Quality Dividend Growth Near 52-Week Lows: Bristol-Myers Squibb Is A Good Bet
09:56am, Tuesday, 30'th May 2023
The author identifies Bristol-Myers Squibb as a potentially attractive investment for long-term dividend growth investors, given its current valuation, yield, and conservative dividend growth. BMY's f
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #17ICML--BMS to Present Late-Breaking Data for Breyanzi in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma at 2023 ICML.
Bristol_Myers says FDA has accepted its non-small lung cancer treatment repotrectinib for priority review
07:43am, Tuesday, 30'th May 2023
Bristol Myers Squibb Co. BMY, -1.15% said Tuesday the U.S. Food and Drug Administration has accepted for priority review its application for repotrectinib as a treatment for patients with certain kind
Bristol Myers (BMY) Thrombosis Drug Gets Fast Track Designation
01:35pm, Friday, 26'th May 2023
Bristol Myers (BMY) obtains Fast Track Designation from the FDA for milvexian, which is being developed in collaboration with Johnson and Johnson's Janssen.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--BMS to Present First Results at ASCO & EHA from Phase 3 COMMANDS Study of Reblozyl in First-Line Treatment.
Bristol Myers (BMY) Reports Pulmonary Fibrosis Study Results
01:39pm, Tuesday, 23'rd May 2023
Bristol Myers' (BMY) idiopathic pulmonary fibrosis drug reduces the rate of lung function decline in a phase II study.
1 Dirt Cheap Dividend Stock to Buy in May
10:07am, Friday, 19'th May 2023
Bristol Myers Squibb's strong pipeline is yielding new approvals that are helping replace older products. Although the company's revenue has been decreasing in the past few quarters, that should chang
Bristol-Myers Squibb Company (BMY) Presents at Bank of America Securities 2023 Health Care Conference (Transcript)
07:02pm, Saturday, 13'th May 2023
Bristol-Myers Squibb Company (NYSE:BMY ) Bank of America Securities 2023 Health Care Conference May 9, 2023 11:40 AM ET Company Participants Adam Lenkowsky - EVP, Head of Commercial Conference Call Pa
Is Bristol-Myers Squibb Stock a Buy Now?
09:17am, Thursday, 11'th May 2023
Bristol-Myers Squibb's stock hasn't been doing well of late, as investors have been discounting it. The company's lack of growth and high debt load hasn't made it an attractive buy.
3 Things About Bristol-Myers Squibb That Smart Investors Know
08:45am, Wednesday, 10'th May 2023
Bristol-Myers is now in a period of relatively less output from its late-stage pipeline. It's going to acquire businesses and make collaboration deals to ameliorate that.
Which Is the Better Passive Income Stock, Eli Lilly or Bristol Myers Squibb?
10:15am, Friday, 05'th May 2023
There are often trade-offs to make when selecting passive income stocks. Eli Lilly's next couple of years will see its revenue burgeon by billions.
